Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Personalized Cancer Vaccines Market Revenue Growth On Track For A 6.4% CAGR Through 2030
The personalized cancer vaccines market size has experienced robust expansion in recent years. It is forecast to rise from $256.65 billion in 2025 to $273.05 billion in 2026, expanding at a compound annual growth rate (CAGR) of 6.4%. The increase observed in the historic period is largely due to advancements in cancer genomics, the substantial unmet need in oncology treatments, the inherent limitations of traditional cancer therapies, the expansion of immunotherapy research, and increased financial support for cancer research.
The personalized cancer vaccines market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $350.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period can be primarily ascribed to the wider adoption of personalized medicine, an increase in cancer incidence rates, advancements in neoantigen discovery, heightened collaboration among biotechnology companies, and favorable regulatory environments. Key trends expected within this period encompass a growing emphasis on personalized immunotherapy, increased application of genomic tumor profiling, the expansion of therapeutic cancer vaccines, greater integration with precision oncology, and elevated clinical trial activity for cancer vaccines.
Get A Free Sample Report With In-Depth Market Insights:
Personalized Cancer Vaccines Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The rising incidence of cancer is anticipated to drive expansion in the personalized cancer vaccine market in the future. Cancer is defined as a collection of illnesses marked by unregulated cell proliferation, capable of invading adjacent tissues and metastasizing throughout the body. The growing occurrence of cancer is fueled by factors such as demographic shifts towards older populations, evolving lifestyles, exposure to environmental agents, and advancements in diagnostic methods. This personalized cancer vaccine market contributes to cancer treatment by offering vaccines uniquely designed for individual patient tumor antigens, thereby boosting the immune system’s capacity to recognize and eradicate malignant cells. A notable example comes from July 2024, when the Australian Institute of Health and Welfare (AIHW), an Australia-based government body, reported an increase in cancer diagnoses in Australia, climbing from 160,570 cases in 2022 to 164,694 cases in 2023, which signifies a considerable rise year-on-year. Consequently, the growing frequency of cancer cases is fueling the expansion of the personalized cancer vaccine market.
Personalized Cancer Vaccines Market Segment Analysis: What Are The Core Market Categories?
The personalized cancer vaccines market covered in this report is segmented –
1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma
3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action
4) By Route Of Administration: Injectables, Other Routes Of Administration
5) By End Use: Hospitals, Clinic, Other End Users
Subsegments:
1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines
2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines
Personalized Cancer Vaccines Market Innovation Trends Shaping Future Development
Major companies operating within the personalized cancer vaccine market are concentrating on developing sophisticated therapeutic solutions, including personalized immunotherapy aimed at specific patient tumor mutations, to enhance treatment accuracy and improve clinical outcomes. Personalized immunotherapy refers to bespoke cancer treatments that leverage a patient’s unique genetic and tumor mutation profile, often delivered via dendritic cell–based vaccines or neoantigen-targeted platforms, to generate a tailored immune response against malignant cells. For instance, in August 2024, UCLA Health, a US-based healthcare organization, initiated a groundbreaking clinical trial to evaluate a personalized cancer vaccine targeting the H3 G34 mutation in diffuse hemispheric gliomas, utilizing dendritic cells to stimulate immunity against the RNA disruptions caused by this aggressive mutation, offering a promising therapeutic avenue for adolescents and young adults who typically face limited treatment choices and poor survival rates.
Personalized Cancer Vaccines Market Top Companies Driving Competitive Growth
Major companies operating in the personalized cancer vaccines market are Moderna Inc., CureVac AG, BioNTech SE, Genentech Inc., Merck & Co. Inc., GlaxoSmithKline plc, Achilles Therapeutics Plc, Evaxion Biotech AS, Geneos Therapeutics Inc., ISA Pharmaceuticals BV, VAXIMM GmbH, EpiVax Therapeutics Inc., Personalis Inc., Catalent Inc., Gritstone bio Inc., Neon Therapeutics Inc., Nouscom AG, Vaccitech plc, Agenus Inc., Transgene SA
View The Full Personalized Cancer Vaccines Market Report:
Personalized Cancer Vaccines Market Geographic Spread And Regional Opportunities
North America was the largest region in the personalized cancer vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model